European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in the white populations, accounting for 20% of all cutaneous malignancies. Factors implicated in cSCC etiopathogenesis include ultraviolet radiation exposure and chronic photoaging, age, male sex, immunosuppression, smoking and genetic factors. A collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation of Research and Treatment of Cancer (EORTC) was formed to update recommendations on cSCC classification, diagnosis, risk stratification, staging and prevention, based on current literature, staging systems and expert consensus. Common cSCCs are typically indolent tumors, and most have a good prognosis with 5-year cure rates of greater than 90%, and a low rate of metastases (<4%). Further risk stratification into low-risk or high-risk common primary cSCC is recommended based on proposed high-risk factors. Advanced cSCC is classified as locally advanced (lacSCC), and metastatic (mcSCC) including locoregional metastatic or distant metastatic cSCC. Current systems used for staging include the American Joint Committee on Cancer (AJCC) 8th edition, the Union for International Cancer Control (UICC) 8th edition, and Brigham and Women's Hospital (BWH) system. Physical examination for all cSCCs should include total body skin examination and clinical palpation of lymph nodes, especially of the draining basins. Radiologic imaging such as ultrasound of the regional lymph nodes, magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography-computed tomography (PET-CT) scans are recommended for staging of high-risk cSCC. Sentinel lymph node biopsy is currently not recommended. Nicotinamide, oral retinoids, and topical 5-FU have been used for the chemoprevention of subsequent cSCCs in high-risk patients but are not routinely recommended. Education about sun protection measures including reducing sun exposure, use of protective clothing, regular use of sunscreens and avoidance of artificial tanning, is recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Most cSCCs carry a UVmutation signature with characteristic C > T or CC > TT dinucleotide mutations, although these may in part be passenger mutations also found in surrounding photoaged skin [74].”
BackgroundAGREE II: advancing guideline development, reporting and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090449 · Cited by 3,790
Green, A., Williams, G., Nèale, R., Hart, V., Leslie, D., Parsons, P., Marks, G. C., Gaffney, P., Battistutta, D., Frost, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12168-2 · Cited by 976 · cited 2×
“Regular use of sunscreen has been reported to be effective in reducing the incidence of SCC in experimental prospective studies [145,149,150].”
BackgroundA Phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention
Chen, A. C., Martin, A. J., Choy, B., Fernández-Peñas, P., Dalziell, R. A., McKenzie, C. A., Scolyer, R. A., Dhillon, H. M., Vardy, J. L., Kricker, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506197 · Cited by 648
Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use
van der Pols, J. C., Williams, G. M., Pandeya, N., Logan, V., & Green, A. C. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0352 · Cited by 396 · cited 2×
“Regular use of sunscreen has been reported to be effective in reducing the incidence of SCC in experimental prospective studies [145,149,150].”
BackgroundTang, J. Y., Fu, T., LeBlanc, E., Manson, J. E., Feldman, D., Linos, E., Vitolins, M. Z., Zeitouni, N. C., Larson, J., & Stefanick, M. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.5967 · Cited by 117 · cited 1×
“Vitamin D3 plus calcium had no statistically significant effect in reducing new self-reported NMSC in a RCT in 36,282 postmenopausal women [177].”
BackgroundCigarette Smoking and the Risks of Basal Cell Carcinoma and Squamous Cell Carcinoma
Dusingize, J. C., Olsen, C. M., Pandeya, N. P., Subramaniam, P., Thompson, B. S., Neale, R. E., Green, A. C., & Whiteman, D. C. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.03.027 · Cited by 75 · cited 1×
“Beside ultraviolet radiation (UVR) exposure (sun exposure and use of tanning beds [47]), which is by far the most important causal factor for cSCC, some others have been implicated such as immunosuppression, BRAF inhibitor (BRAFi) single agent therapy, b-HPV subtypes [48,49] and smoking [50,51].”
BackgroundYoul, P. H., Soyer, H. P., Baade, P. D., Marshall, A. L., Finch, L., & Janda, M. (2015) · Preventive Medicine · doi:10.1016/j.ypmed.2014.12.009 · Cited by 56
Cited by
Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353
“Cemiplimab was the first drug approved by the FDA for the treatment of CSCC, and it is also mentioned and recommended in the 2020 European interdisciplinary guidelines (issued by the EDF, EADO, and EORTC) as the first-line therapy for cancer patients who cannot be treated with radiotherapy or surgery [47].”
BackgroundCutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches
Fania, L., Didona, D., Di Pietro, F. R., Verkhovskaia, S., Morese, R., Paolino, G., Donati, M., Ricci, F., Coco, V., Ricci, F., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9020171 · Cited by 255
Metadata
- Authors
- Stratigos, A. J., Garbe, C., Dessinioti, C., Lebbe, C., Bataille, V., Bastholt, L., Dreno, B., Fargnoli, M. C., Forsea, A. M., Frenard, C., Harwood, C. Α., Hauschild, A., Hoeller, C., Kandolf-Sekulovic, L., Kaufmann, R., Kelleners-Smeets, N. W., Malvehy, J., del Marmol, V., Middleton, M. R., Moreno-Ramirez, D., Pellecani, G., Peris, K., Saiag, P., van den Beuken-van Everdingen, M. H. J., Vieira, R., Zalaudek, I., Eggermont, A. M. M., & Grob, J.-J.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 128
- Pages
- 60-82
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W3007541271
- Cited by
- 242
- References
- 8
- FWCI
- 21.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. https://app.cochat.ai/papers/10.1016/j.ejca.2020.01.007
- The paper
- Stratigos, A. J., Garbe, C., Dessinioti, C., Lebbe, C., Bataille, V., Bastholt, L., Dreno, B., Fargnoli, M. C., Forsea, A. M., Frenard, C., Harwood, C. Α., Hauschild, A., Hoeller, C., Kandolf-Sekulovic, L., Kaufmann, R., Kelleners-Smeets, N. W., Malvehy, J., del Marmol, V., Middleton, M. R., . . . Grob, J.-J. (2020). European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2020.01.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.